Remote Conditioning Device Tested After Moderate Back-of-Brain Stroke
Tests a remote ischemic conditioning device in adults with acute moderate posterior stroke.
Plain-language title generated from the registry record
Registry title: Remote Ischemic Conditioning for Acute Moderate Posterior Ischemic Stroke
Key facts
- Where
- Shenyang, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a moderate stroke in the back part of the brain, treated within 48 hours of the start of symptoms.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Stroke from a blocked blood vessel in the back part of the brain (posterior circulation), confirmed by CT or MRI. NIHSS score 6-16 at randomization, with a consciousness item 1a score of 0-1.
- Earlier treatment
- Treatment must start within 48 hours of onset. People who had clot-dissolving drugs through a vein or endovascular therapy can join. Any earlier stroke must have left no significant disability (modified Rankin Scale score ≤1).
Main reasons for not taking part
- Bleeding in the brain or around the brain
- Uncontrolled severe high blood pressure (above 180 mmHg systolic or 110 mmHg diastolic despite treatment)
- Narrowing of 50% or more in the subclavian artery, or subclavian steal syndrome
- Serious injury or vascular problem in the upper arm or limb that rules out the arm cuff treatment
- Life expectancy of less than half a year, or another clinical trial within 3 months
Read by machine on 9 November 2026.
Where in China
- Department of Neurology, General Hospital of Northern Theater CommandShenyang, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- General Hospital of Shenyang Military Region
- Trial code
- NCT06931535
- Record updated
- 17 September 2026
- Original description
A substantial body of basic and clinical research has demonstrated the protective effects of remote ischemic conditioning (RIC) in ischemic stroke. While these clinical studies support the safety of RIC, the neuroprotective benefits of RIC in acute ischemic stroke (AIS) patients lack robust evidence due to small sample sizes, heterogeneous RIC protocols, and variability in the severity of neurological deficits among study populations. Our recent multicenter randomized clinical trial, the RICAMIS study, investigated the efficacy of RIC in patients with acute moderate ischemic stroke. The results showed that RIC administered within 48 hours of onset significantly improved 90-day neurological outcomes in patients with moderate stroke severity. It is well established that anterior circulation stroke (ACS) and posterior circulation stroke (PCS) differ in multiple aspects, including anatomical structure, collateral circulation, blood supply, clinical manifestations, prognosis, ischemic tolerance time, and treatment response. For instance, compared to the anterior circulation, the posterior circulation has poorer collateral circulation, a higher proportion of stroke etiologies attributed to atherosclerosis, and longer ischemic tolerance time. Consequently, intravenous thrombolysis and endovascular therapy may offer a more extended therapeutic time window for PCS patients. A prespecified subgroup analysis of the RICAMIS study revealed that patients with PCS derived greater benefit from RIC than those with ACS. However, this finding requires further validation through prospective studies, as prior research has never specifically examined the efficacy of RIC in PCS patients.Read full original descriptionShow less
Remote Ischemic Conditioning for Acute Moderate Posterior Ischemic Stroke (RICAMIS2): a Prospective, Random, Open Label, Blinded End Point, Multi-center Study
A substantial body of basic and clinical research has demonstrated the protective effects of remote ischemic conditioning (RIC) in ischemic stroke. While these clinical studies support the safety of RIC, the neuroprotective benefits of RIC in acute ischemic stroke (AIS) patients lack robust evidence due to small sample sizes, heterogeneous RIC protocols, and variability in the severity of neurological deficits among study populations. Our recent multicenter randomized clinical trial, the RICAMIS study, investigated the efficacy of RIC in patients with acute moderate ischemic stroke. The results showed that RIC administered within 48 hours of onset significantly improved 90-day neurological outcomes in patients with moderate stroke severity. It is well established that anterior circulation stroke (ACS) and posterior circulation stroke (PCS) differ in multiple aspects, including anatomical structure, collateral circulation, blood supply, clinical manifestations, prognosis, ischemic tolerance time, and treatment response. For instance, compared to the anterior circulation, the posterior circulation has poorer collateral circulation, a higher proportion of stroke etiologies attributed to atherosclerosis, and longer ischemic tolerance time. Consequently, intravenous thrombolysis and endovascular therapy may offer a more extended therapeutic time window for PCS patients. A prespecified subgroup analysis of the RICAMIS study revealed that patients with PCS derived greater benefit from RIC than those with ACS. However, this finding requires further validation through prospective studies, as prior research has never specifically examined the efficacy of RIC in PCS patients.
Based on the above discussion, this study aims to investigate the efficacy and safety of RIC in patients with acute moderate PCS.
Inclusion: Age ≥18 years; Time from onset to treatment: ≤48 hours; Posterior circulation ischemic stroke confirmed by CT or MRI, including patients who have received intravenous thrombolysis or endovascular therapy; NIHSS score at randomization: 6-16, with an item 1a (level of consciousness) score of 0-1; First-ever stroke or prior stroke without significant residual disability (modified Rankin Scale score ≤1); Signed informed consent.
Exclusion: intracerebral hemorrhage or subarachnoid hemorrhage；; Uncontrolled severe hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg despite antihypertensive therapy)；; Subclavian artery stenosis ≥ 50% or subclavian steal syndrome; Comorbidity with any serious diseases and life expectancy is less than half a year; Intracranial tumor, arteriovenous malformation or aneurysm; Severe abnormalities in coagulation; Any contraindication for remote ischemic adaptation: the upper limb has serious soft tissue injury, fracture or vascular injury, distal upper limb perivascular lesions, etc; Participating in other clinical trials within 3 months; Patients not suitable for this clinical studies considered by researcher.